EGFR and pancreatic neoplasm: Previously, mutation and activation of epidermal growth factor receptor (EGFR) have been determined in a variety of solid tumours, including breast, head and neck, non-small-cell lung, gastric, colorectal and pancreatic cancers and mostly associated with a poor prognosis [8,9].